Evidence map›Paper›PMID 39017887›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

In Vivo CRISPR/Cas9-Mediated Gene Ablation in Murine B Cells.

Kumari Anupam, Brian J Laidlaw

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kumari AnupamDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Brian J LaidlawDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA. brian.laidlaw@wustl.edu.

Funding

Enhancing the antiviral memory B cell responseDP2AI169978 · NIAID · WASHINGTON UNIVERSITY · PI LAIDLAW, BRIAN · 2021 to 2024
$2.2M
Lung-resident memory B cell development and function following influenza virus infectionK22AI153015 · NIAID · WASHINGTON UNIVERSITY · PI LAIDLAW, BRIAN · 2020 to 2021
$270k
NIAID NIH HHS DP2 AI169978NIAID NIH HHS K22 AI153015
6 · The paper itself

Abstract

CRISPR-Cas9 genome editing is a powerful tool for assessing the functional role of candidate genes. In vitro CRISPR/Cas9 screens have been used to rapidly assess the role of thousands of genes in the differentiation and function of immune populations. However, the physiological relevance of a gene is often dependent on signals received in the tissue microenvironment, such as exposure to growth factors, chemokines, cytokines, and cell contact-dependent signals, which may not be recapitulated in an in vitro setting. Additionally, in vitro approaches are not sufficient to induce the differentiation of all cell populations limiting the cell types that can be screened. This has posed a major barrier to understanding the genes regulating the differentiation of germinal center B cells. Here, we describe an approach to perform an in vivo Crispr-Cas9 screen to specifically ablate genes in activated B cells. Using this approach, we have been able to reveal novel transcriptional regulators of germinal center B cell differentiation following viral infection.

Indexed as

B-LymphocytesCell DifferentiationCRISPR-Cas SystemsGene EditingAnimalsGene DeletionGerminal CenterMiceRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsB cellsBone marrow chimerasCRISPR-Cas9 screenRetroviral transductionSingle-guide RNAs

Identifiers

PMID39017887
PMCPMC11706329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.